Our studies in cultured cells, primary differentiated and undifferentiated normal hematopoietic cells, and the investigation of leukemia cell growth in an in vivo model coherently illustrate that MA49 kills leukemia cells with FLT3-ITD significantly and without a detectable negative impact on normal differentiated and undifferentiated cells and tissues. This evidence concerns the gene FLT3 and leukemia.